JP2019207242A5 - - Google Patents

Download PDF

Info

Publication number
JP2019207242A5
JP2019207242A5 JP2019126244A JP2019126244A JP2019207242A5 JP 2019207242 A5 JP2019207242 A5 JP 2019207242A5 JP 2019126244 A JP2019126244 A JP 2019126244A JP 2019126244 A JP2019126244 A JP 2019126244A JP 2019207242 A5 JP2019207242 A5 JP 2019207242A5
Authority
JP
Japan
Prior art keywords
interleukin
blood sample
whole blood
cells
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019126244A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019207242A (ja
Filing date
Publication date
Priority claimed from KR1020110012983A external-priority patent/KR20120093002A/ko
Application filed filed Critical
Publication of JP2019207242A publication Critical patent/JP2019207242A/ja
Publication of JP2019207242A5 publication Critical patent/JP2019207242A5/ja
Priority to JP2021197948A priority Critical patent/JP2022043119A/ja
Pending legal-status Critical Current

Links

JP2019126244A 2011-02-14 2019-07-05 がんを診断する方法およびnk細胞活性の測定を使用した診断キット Pending JP2019207242A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021197948A JP2022043119A (ja) 2011-02-14 2021-12-06 がんを診断する方法およびnk細胞活性の測定を使用した診断キット

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2011-0012983 2011-02-14
KR1020110012983A KR20120093002A (ko) 2011-02-14 2011-02-14 Nk 세포의 활성 측정을 이용한 암 진단 방법 및 진단 키트

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2017069908A Division JP6798922B2 (ja) 2011-02-14 2017-03-31 がんを診断する方法およびnk細胞活性の測定を使用した診断キット

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021197948A Division JP2022043119A (ja) 2011-02-14 2021-12-06 がんを診断する方法およびnk細胞活性の測定を使用した診断キット

Publications (2)

Publication Number Publication Date
JP2019207242A JP2019207242A (ja) 2019-12-05
JP2019207242A5 true JP2019207242A5 (cg-RX-API-DMAC7.html) 2020-02-06

Family

ID=46672988

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2013553044A Active JP6629497B2 (ja) 2011-02-14 2012-02-10 がんを診断する方法およびnk細胞活性の測定を使用した診断キット
JP2017069908A Active JP6798922B2 (ja) 2011-02-14 2017-03-31 がんを診断する方法およびnk細胞活性の測定を使用した診断キット
JP2019126244A Pending JP2019207242A (ja) 2011-02-14 2019-07-05 がんを診断する方法およびnk細胞活性の測定を使用した診断キット
JP2021197948A Withdrawn JP2022043119A (ja) 2011-02-14 2021-12-06 がんを診断する方法およびnk細胞活性の測定を使用した診断キット
JP2023076634A Active JP7660605B2 (ja) 2011-02-14 2023-05-08 がんを診断する方法およびnk細胞活性の測定を使用した診断キット

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2013553044A Active JP6629497B2 (ja) 2011-02-14 2012-02-10 がんを診断する方法およびnk細胞活性の測定を使用した診断キット
JP2017069908A Active JP6798922B2 (ja) 2011-02-14 2017-03-31 がんを診断する方法およびnk細胞活性の測定を使用した診断キット

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021197948A Withdrawn JP2022043119A (ja) 2011-02-14 2021-12-06 がんを診断する方法およびnk細胞活性の測定を使用した診断キット
JP2023076634A Active JP7660605B2 (ja) 2011-02-14 2023-05-08 がんを診断する方法およびnk細胞活性の測定を使用した診断キット

Country Status (20)

Country Link
US (2) US11442069B2 (cg-RX-API-DMAC7.html)
EP (1) EP2676139B1 (cg-RX-API-DMAC7.html)
JP (5) JP6629497B2 (cg-RX-API-DMAC7.html)
KR (3) KR20120093002A (cg-RX-API-DMAC7.html)
CN (1) CN103370622B (cg-RX-API-DMAC7.html)
AU (2) AU2012219184A1 (cg-RX-API-DMAC7.html)
BR (1) BR112013020454B1 (cg-RX-API-DMAC7.html)
CA (1) CA2826053C (cg-RX-API-DMAC7.html)
CL (1) CL2013002361A1 (cg-RX-API-DMAC7.html)
DK (1) DK2676139T3 (cg-RX-API-DMAC7.html)
EA (1) EA038959B1 (cg-RX-API-DMAC7.html)
ES (1) ES2797549T3 (cg-RX-API-DMAC7.html)
IL (1) IL227952B (cg-RX-API-DMAC7.html)
MX (1) MX361731B (cg-RX-API-DMAC7.html)
MY (1) MY175351A (cg-RX-API-DMAC7.html)
RU (1) RU2635194C2 (cg-RX-API-DMAC7.html)
SG (1) SG192247A1 (cg-RX-API-DMAC7.html)
TW (2) TWI668445B (cg-RX-API-DMAC7.html)
UA (1) UA120697C2 (cg-RX-API-DMAC7.html)
WO (1) WO2012110878A2 (cg-RX-API-DMAC7.html)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20120093002A (ko) 2011-02-14 2012-08-22 (주)에이티젠 Nk 세포의 활성 측정을 이용한 암 진단 방법 및 진단 키트
KR101520534B1 (ko) 2012-05-07 2015-05-21 고려대학교 산학협력단 말초혈액단핵구 유래 자연 살해세포의 유도 및 증식 방법
EP3066474B1 (en) 2013-11-05 2019-04-03 Agency For Science, Technology And Research Bladder carcinoma biomarkers
JP6073417B2 (ja) * 2015-06-26 2017-02-01 チャ バイオテック カンパニー リミテッド 自然殺害細胞増殖方法、及び自然殺害細胞増殖用の組成物
KR101926166B1 (ko) * 2016-05-24 2018-12-06 재단법인 아산사회복지재단 수용체 시너지 활성을 이용한 nk 세포의 활성도 검사 방법 및 이를 이용한 nk 세포의 활성도가 관련된 질환의 진단 방법
WO2017204446A2 (ko) * 2016-05-24 2017-11-30 울산대학교 산학협력단 수용체 시너지 활성을 이용한 nk 세포의 활성도 검사 방법 및 이를 이용한 nk 세포의 활성도가 관련된 질환의 진단 방법
CN107686828A (zh) * 2016-08-04 2018-02-13 英普乐孚生物技术(上海)有限公司 一种nk细胞无血清培养基
CN106085958A (zh) * 2016-08-04 2016-11-09 英普乐孚生物技术(上海)有限公司 一种nk细胞的制备方法
CN106222140A (zh) * 2016-08-04 2016-12-14 英普乐孚生物技术(上海)有限公司 一种nk细胞无血清培养基及其配制方法
JP7136790B2 (ja) 2017-02-17 2022-09-13 ブリストル-マイヤーズ スクイブ カンパニー アルファ-シヌクレインに対する抗体およびその使用
US11629340B2 (en) 2017-03-03 2023-04-18 Obsidian Therapeutics, Inc. DHFR tunable protein regulation
KR102090698B1 (ko) * 2017-08-24 2020-04-23 연세대학교 산학협력단 암의 진단, 모니터링, 또는 예후 예측을 위해 생체 외 인터페론-감마의 양을 측정하는 방법
CN115710576A (zh) 2018-02-01 2023-02-24 Nkmax有限公司 产生天然杀伤细胞的方法和用于治疗癌症的组合物
WO2020168250A1 (en) * 2019-02-14 2020-08-20 Research Institute At Nationwide Children's Hospital Use of a stimulating agent to assay immune cell potency
CN114615886A (zh) * 2019-08-29 2022-06-10 得克萨斯大学体系董事会 细胞冷冻保存培养基
CA3153542A1 (en) * 2019-09-25 2021-04-01 Leto Laboratories Co., Ltd Recombinant interleukin-15 analog
EP4048296A4 (en) * 2019-11-29 2024-01-24 Nkmax Co., Ltd. Method of producing natural killer cells and compositions thereof
JP7849854B2 (ja) * 2020-07-29 2026-04-22 国立大学法人東北大学 シヌクレイノパチーを予防又は治療するために使用されるペプチド
CN113533729B (zh) * 2021-06-15 2024-09-06 北京大学人民医院 一种鉴定aml患者骨髓中nk细胞耗竭的研究方法及其应用
KR20240117150A (ko) * 2021-12-17 2024-07-31 유니버시티 오브 켄트 재조합 생물학적 분자의 생산을 위한 서열 및 방법
KR20230156518A (ko) 2022-05-06 2023-11-14 (주)다이오진 엑소좀 내의 인터페론 감마 유전자 측정을 이용한 암 조기 진단 방법 및 진단 키트
CN115247149B (zh) * 2022-08-22 2023-06-16 华域生物科技(天津)有限公司 适用于nk细胞的培养基组合物及培养方法
CN115855779A (zh) * 2023-01-18 2023-03-28 山东康华生物医疗科技股份有限公司 一种定量检测nk细胞活性的磁微粒化学发光试剂盒及其检测方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2635088A (en) 1987-12-04 1989-06-08 Du Pont Merck Pharmaceutical Company, The Immobilized interleukin 2 and interleukin 2 containing a carboxyl-terminal extension
CA2168584C (en) * 1993-08-09 2008-10-14 Edward Baral A method for sensitization of cancer cells for killer cell mediated lysis
JP2000510813A (ja) * 1995-02-06 2000-08-22 ジェネテイックス・インスティテュート・インコーポレイテッド Il−12用処方
US20060057651A1 (en) * 2000-12-08 2006-03-16 Bowdish Katherine S Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
JP3995248B2 (ja) 2001-08-13 2007-10-24 準二郎 土山 エプスタインバーウイルス陰性のnk細胞株
AU2002321931A1 (en) * 2001-11-20 2003-06-10 Atgen Co., Ltd. Novel peptides conferring environmental stress resistance and fusion proteins including said peptides
WO2003082206A2 (en) * 2002-03-26 2003-10-09 Centocor, Inc. Multiple sclerosis-related immunoglobulin derived proteins, compositions, methods and uses
JP2004305095A (ja) 2003-04-07 2004-11-04 Limuloid Science Kk 細胞活性化検出方法
CN1297567C (zh) * 2003-06-13 2007-01-31 马菁 具有抗肿瘤功能的双功能融合蛋白及其制备方法和应用
ES2356154T3 (es) * 2003-07-21 2011-04-05 Transgene S.A. Citoquinas multifuncionales.
WO2005013950A2 (en) 2003-08-08 2005-02-17 Avanir Pharmaceuticals Selective pharmacologic inhibition of protein trafficking and related methods of treating human diseases
SG148161A1 (en) 2003-11-05 2008-12-31 Palingen Inc Enhanced b cell cytotoxicity of cdim binding antibody
KR100565764B1 (ko) 2005-05-02 2006-03-28 (주)에이티젠 환경 스트레스에 내성을 부여하는 신규한 펩타이드 및 이를포함하는 융합 단백질
US20050203010A1 (en) 2003-11-14 2005-09-15 Atgen Co., Ltd. Novel peptides conferring environmental stress resistance and fusion proteins including said peptides
JP4653465B2 (ja) 2004-10-25 2011-03-16 泰信 小林 ナチュラルキラー細胞の増殖促進方法およびそれに用いる培養組成物
WO2006110577A2 (en) * 2005-04-08 2006-10-19 Morningside Venture Investments Limited Use of fril proteins for reducing the production of pro-inflammatory cytokines
AU2007277050A1 (en) * 2006-07-28 2008-01-31 The Research Foundation Of State University Of New York Methods and kits for measurement of lymphocyte function
WO2008070647A1 (en) * 2006-12-07 2008-06-12 Wyeth Methods and compositions for assessing il-12 or the neutralization of il-12 in a sample
AU2008204433B2 (en) 2007-01-11 2014-03-13 Novo Nordisk A/S Anti-KIR antibodies, formulations, and uses thereof
EP2048237A1 (en) 2007-10-05 2009-04-15 Avir Green Hills Biotechnology Research Development Trade Ag Replication deficient Influenza virus for the expression of heterologous sequences
KR20120093002A (ko) 2011-02-14 2012-08-22 (주)에이티젠 Nk 세포의 활성 측정을 이용한 암 진단 방법 및 진단 키트

Similar Documents

Publication Publication Date Title
JP2022043119A5 (cg-RX-API-DMAC7.html)
JP7660605B2 (ja) がんを診断する方法およびnk細胞活性の測定を使用した診断キット
Chen et al. Different expression patterns of plasma Th1‐, Th2‐, Th17‐and Th22‐related cytokines correlate with serum autoreactivity and allergen sensitivity in chronic spontaneous urticaria
Witkowska On the role of sIL‐2R measurements in rheumatoid arthritis and cancers
Townson et al. Characterization of mouse CCX‐CKR, a receptor for the lymphocyte‐attracting chemokines TECK/mCCL25, SLC/mCCL21 and MIP‐3β/mCCL19: comparison to human CCX‐CKR
Hidvégi et al. Correlation between T-cell and mast cell activity in patients with chronic urticaria
HISAEDA et al. Interferon-γ and tumor necrosis factor-α levels in sera and whey of cattle with naturally occurring coliform mastitis
Hapnes et al. Radioligand-binding assay reveals distinct autoantibody preferences for type I interferons in APS I and myasthenia gravis subgroups
Matsuda et al. Cytokine mRNA expression profiles in rats infected with the intestinal nematode Nippostrongylus brasiliensis
US5766864A (en) Method of measuring interferon acitivity
Naftali et al. Interleukin-18 and its binding protein in patients with inflammatory bowel disease during remission and exacerbation
EP3468578A1 (en) Uses of il-41
Wakatabi et al. The levels of soluble ST2 in sera and bullous fluid from patients with bullous pemphigoid
Krakauer A sensitive, specific immunobioassay for quantitation of human interleukin 6
Al-bassam et al. Biomarker significance of interleukin-18 in juvenile idiopathic arthritis
KR102158759B1 (ko) 사이토카인 분석을 통한 관절염 치료제 스크리닝 방법
Marzinotto et al. Autoantibody binding in liquid phase to IL-2 in human sera is not type 1 diabetes specific
Valencia et al. Overview of the cytokine assay multiverse: Systems and applications
Islam et al. Chemokine and chemokine receptor analysis
Adhikari et al. Validation of Metabolic and Immunologic Biomarkers TNF-a, IGF, IL-6, CRP and Hair Cortisol in the Common Marmoset
Schaniel et al. A novel CC chemokine ABCD-1, produced by dendritic cells and activated B cells, exclusively attracts activated T lymphocytes
Adelman Functional assessment of mononuclear leukocytes
RO135591A0 (ro) Metodă de stabilire a unui set de interleukine-citokine-chemokine imunologic relevante, în model animal de psoriazis tratat cu igy obţinut din oul hiperimun
Krakauer et al. A method for correcting for the variability of inhibitory effects of soluble human interleukin 1 receptor II measured by different ELISAS
Vivo Preferential Role for NF